Editorial: Evaluating the Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinemia

被引：1
|
作者：
Bhardwaj, Nakul J. [1 ]
Kim, Rebecca G. [1 ]
机构：
[1] Univ Utah Hlth, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Salt Lake City, UT 84132 USA
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2025年 / 61卷 / 04期
关键词：
D O I：
10.1111/apt.18453
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：727 / 728
页数：2
相关论文
共 50 条
  • [31] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [32] Machine Learning Identifies Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Diabetes Mellitus
    Nabrdalik, Katarzyna
    Kwiendacz, Hanna
    Irlik, Krzysztof
    Hendel, Mirela
    Drozdz, Karolina
    Wijata, Agata M.
    Nalepa, Jakub
    Janota, Oliwia
    Wojcik, Wiktoria
    Gumprecht, Janusz
    Lip, Gregory Y. H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (08): : 2029 - 2038
  • [33] Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study
    Fukunaga, Kensaku
    Morishita, Asahiro
    Imachi, Hitomi
    Oura, Kyoko
    Sato, Seisuke
    Kobayashi, Toshihiro
    Saheki, Takanobu
    Yoshimura, Takafumi
    Komori, Kurumi
    Nakahara, Mai
    Tadokoro, Tomoko
    Fujita, Koji
    Tani, Joji
    Kobara, Hideki
    Murao, Koji
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1498 - 1506
  • [34] Pharmacological treatment options for metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review
    Konings, Laura A. M.
    Miguelanez-Matute, Lorena
    Boeren, Anna M. P.
    van de Luitgaarden, Inge A. T.
    Dirksmeier, Femme
    de Knegt, Rob J.
    Tushuizen, Maarten E.
    Grobbee, Diederick E.
    Holleboom, Adriaan G.
    Cabezas, Manuel Castro
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2025, 55 (04)
  • [35] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [36] Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients
    Babu, Ambrin Farizah
    Palomurto, Saana
    Karja, Vesa
    Kakela, Pirjo
    Lehtonen, Marko
    Hanhineva, Kati
    Pihlajamaki, Jussi
    Mannisto, Ville
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (12) : 2103 - 2110
  • [37] Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes
    Della Pepa, G.
    Lupoli, R.
    Masulli, M.
    Boccia, R.
    De Angelis, R.
    Gianfrancesco, S.
    Piccolo, R.
    Rainone, C.
    Rivellese, A. A.
    Annuzzi, G.
    Bozzetto, L.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2024, 47 (09) : 2371 - 2378
  • [38] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [39] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [40] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
12345